Medication info

Rinategen Duo Tablet 2.5/850 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Alvogen Korea Co., Ltd.
Appearance
Bright orange, oval-shaped, biconvex, film-coated tablet
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201901555 · Approved 2019.03.13

This product's status changed to Approval withdrawn on 2024.01.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment experience in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily; it may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medication should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Alvogen Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication is primarily used to help control blood glucose levels in patients with type 2 diabetes. It is prescribed for cases where there has been no initial experience with diabetes drug therapy or where blood glucose control is difficult with monotherapy. It can also be administered as an alternative or in combination therapy when sufficient blood glucose control is not achieved with metformin monotherapy or a combination of linagliptin and metformin. It can enhance blood glucose control when used together with sulfonylureas, insulin, and empagliflozin. This medication effectively improves blood glucose control when combined with various treatment options.

How to take

Adult dose

The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment experience in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily; it may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medication should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication contains metformin hydrochloride, which can rarely cause a serious side effect known as lactic acidosis, so caution is required. In particular, this medication should not be administered to patients with allergies to any of its components, type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. Patients with severely impaired kidney function, severe liver dysfunction, dehydration, or acute conditions such as severe infections should also avoid using this medication. Additionally, it is recommended that this medication not be administered to women who are pregnant or breastfeeding. This medication carries a risk of hypoglycemia; therefore, caution is needed regarding the possibility of hypoglycemia when used in combination with sulfonylureas or insulin. To reduce the risk of lactic acidosis, kidney function should be periodically monitored, and if kidney function deteriorates, the use of this medication should be avoided or discontinued. In cases of acute kidney function deteriorating, cardiopulmonary disease, or sepsis, it is safe to temporarily discontinue this medication. Patients should consult a doctor immediately if symptoms such as abdominal pain, muscle pain, or weakness occur while taking this medication. This medication can cause rare skin disorders such as pancreatitis or similar conditions; therefore, if persistent and severe abdominal pain or blisters on the skin appear, the medication should be discontinued, and the patient should seek medical attention. The metformin component can lower vitamin B12 levels, so regular checks for vitamin B12 deficiency are recommended during long-term use. Potential drug interactions may occur; therefore, patients should inform their doctors or pharmacists of any currently taken medications. Special attention to kidney function is needed when taken with diuretics, antihypertensives, or non-steroidal anti-inflammatory drugs that may affect kidney function. This medication should be avoided during pregnancy, and women planning to become pregnant are advised to consult a doctor before deciding on treatment options. The use of this medication is also recommended to be avoided during breastfeeding. Elderly patients commonly have reduced kidney function; thus, kidney function should be assessed before starting this medication, and monitoring should be conducted regularly. Caution may be needed when driving or operating machinery while taking this medication, though no specific studies on its effects have been conducted yet. In case of overdose, serious side effects such as lactic acidosis may occur. Immediate medical treatment is necessary, and blood dialysis may be required. This medication should be stored away from moisture and kept out of reach of children, and transferring it to another container should be avoided.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • dysgeusia
  • cough
  • decreased appetite
Show 95 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • pseudopemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increase in lipase
  • increase in amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • bruising
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • allergic rhinitis
  • exercise-induced dyspnea
  • wet cough
  • runny nose
  • osteoarthritis
  • limb pain
  • itching
  • hypertension
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to store it at room temperature between 1°C and 30°C to maintain its effectiveness.

Appearance and packaging

Appearance

Bright orange, oval-shaped, biconvex, film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.